证券代码：002872 证券简称：ST 天圣 公告编号：2024-016 天圣制药集团股份有限公司 第六届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 公司独立董事分别向董事会提交了《2023 年度独立董事述职报告》，并将 在 2023 年度股东大会上进行述职。公司独立董事分别向董事会提交了《独立董 事关于独立性的自查报告》，董事会对此进行评估并出具了《董事会对独立董 事独立性评估的专项意见》。 具体内容详见同日刊登于巨潮资讯网（http://www.cninfo.com.cn）上的 《2023 年度董事会工作报告》、《2023 年度独立董事述职报告》、《董事会对 独立董事独立性评估的专项意见》。 该议案尚需提交公司 2023 年度股东大会审议。 （二）审议通过《关于公司 2023 年度总经理工作报告的议案》 1 一、董事会会议召开情况 天圣制药集团股份有限公司（以下称"公司"）第六届董事会第四次会议 于 2024 年 4 月 24 日以现场及通讯方式在公司会议室召开。2024 年 4 月 12 日， 以电话及邮件的通知方式发出会议 ...

天圣制药集团股份有限公司 关于续聘公司 2024 年度审计机构的公告 证券代码：002872 证券简称：ST 天圣 公告编号：2024-025 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、天圣制药集团股份有限公司（以下简称"公司"）2023年度财务报告被 北京兴华会计师事务所（特殊普通合伙）（以下简称"北京兴华"）出具了保 留意见的审计报告（[2024]京会兴审字第 00830012 号）。 2、公司续聘会计师事务所相关事项符合财政部、国务院国资委、证监会印 发的《国有企业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4号） 的规定。 公司于 2024年 4月 24日召开的第六届董事会第四次会议、第六届监事会第 二次会议审议通过了《关于续聘公司 2024 年度审计机构的议案》，同意继续聘 请北京兴华会计师事务所（特殊普通合伙）为公司 2024 年度财务和内部控制审 计机构。该议案在提交董事会审议前已经公司审计委员会全票审议通过。该事 项尚需提交公司 2023 年度股东大会审议。现将有关情况公告如下： 一、拟续聘会计师事务所的基本情况 ...

天圣制药集团股份有限公司 2023 年度内部控制自我评价报告 天圣制药集团股份有限公司全体股东： 为进一步加强和规范公司内部控制，提高公司经营管理水平和风险防范能力， 促进公司规范运作和健康发展，维护全体股东和利益相关者的合法权益，根据《企 业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称 "企业内部控制规范体系"），结合《公司章程》等规定，公司全面建立健全内 部控制制度，有效落实相关制度规范的要求，强化对内控制度执行的监督检查， 不断提高治理水平，促进企业规范运作，有效防范经营决策及管理风险，确保公 司的稳健经营。在内部控制日常监督和专项监督的基础上，我们对公司截至 2023 年 12 月 31 日（内部控制评价报告基准日）的内部控制工作有效性进行了自我评 价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并 ...

天圣制药集团股份有限公司 2023 年度独立董事述职报告 独立董事 邓瑞平 各位股东及股东代表： 本人作为天圣制药集团股份有限公司（以下简称"天圣制药"、"公司"） 的第五届董事会独立董事，因连续任期满六年于 2023 年 5 月 19 日离任。在 2023 年度任职期间，本人严格按照《公司法》、《证券法》、《上市公司独立董事管 理办法》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作》、《公司章程》及《独立董事工作制度》等相关法律及规章指引的规定 和要求，诚信、勤勉、独立地履行独立董事职责，积极出席相关会议，维护公司 利益和股东合法权益，对公司规范、稳定、健康地发展起到了积极的推动作用。 现将本人在 2023 年任职期间的工作情况向各位股东及股东代表进行汇报。 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 邓瑞平，1963 年 8 月出生，中国国籍，无境外永久居留权，武汉大学国际 经济法博士学位，西南大学法学教授，长期从事国际经济法、海商法和国际商事 仲裁法的教学、科研和实务工作。2017 年 1 月至 2023 年 5 月，任天圣制药集团 股份有限公司独立董事， ...

证券代码：002872 证券简称：ST 天圣 公告编号：2024-022 天圣制药集团股份有限公司 关于公司 2024 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 1、预计 2024 年度日常关联交易的基本情况 天圣制药集团股份有限公司（以下简称"公司"）及子公司因日常生产经 营需要，预计 2024 年度与关联方重庆医药集团长圣医药有限公司（以下简称 "长圣医药"）及其子公司发生关联交易总金额 11,270.00 万元，上年同类交易 实际发生总额为 7,235.55 万元。 2、审议程序和关联董事回避情况 公司于 2024 年 4 月 24 日召开的第六届董事会第四次会议，以 5 票同意、0 票弃权、0 票反对的表决结果审议通过了公司《关于公司 2024 年度日常关联交 易预计的议案》，关联董事刘爽、张娅已回避表决。该事项已经独立董事专门 会议审议通过，全体独立董事同意该事项。该议案尚需提交公司 2023 年度股东 大会审议，关联股东刘群、刘爽应回避表决。本次预计的关联交易额度有 ...

天圣制药集团股份有限公司 2023 年度监事会工作报告 2023 年，公司监事会严格按照《公司法》、《证券法》等法律、法规和《公 司章程》、《监事会议事规则》的有关规定，关注公司内部控制体系的建设和运行 情况，及时掌握公司的财务状况，对公司长期发展规划、重大项目、公司生产经 营活动、财务状况和公司董事、高级管理人员的履职情况进行监督，切实履行了 监督职责，维护全体股东和公司的合法利益。现就公司监事会 2023 年度履职情 况报告如下： 一、公司监事会 2023 年工作情况 （一）监事会会议召开情况 2023 年，公司监事会共召开 4 次会议，会议的召开与表决程序均符合《公 司法》、《公司章程》等法律法规和规范性文件的规定，具体情况如下： | 序号 | 会议届次 | 召开时间 | 会议议题 | | --- | --- | --- | --- | | | | | 1、《关于公司 2022 年度监事会工作报告的议案》 | | | | | 2、《关于公司 2022 年年度报告及摘要的议案》 | | | | | 年度财务决算报告的议案》 3、《关于公司 2022 | | | | | 4、《关于公司 2022 年度利润分 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2024-029 天圣制药集团股份有限公司 关于 2023 年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本次计提资产减值准备情况概述 （一）本次计提资产减值准备的原因 天圣制药集团股份有限公司（以下简称"公司"）根据《深圳证券交易所股 票上市规则》、《企业会计准则》等相关规定，为更加真实、准确反映公司截至 2023 年 12 月 31 日的财务状况、资产价值及经营成果，基于谨慎性原则，公司 对截至 2023 年 12 月 31 日合并报表范围内的各类资产进行了全面检查和减值测 试，对部分可能发生信用减值、资产减值的资产计提了减值准备。 （二）本次计提资产减值准备的资产范围、总金额和拟计入的报告期间 经公司对截至 2023 年 12 月 31 日合并报表范围内的资产进行全面清查和资 产减值测试后，公司计提有关资产减值准备合计 2,456.1117 万元。本次计提资产 减值准备计入的报告期间为 2023 年 1 月 1 日至 2023 年 12 月 31 日。具体情况如 下 ...

Financial Performance - The company's operating revenue for 2023 was ¥579,334,659.15, a decrease of 4.56% compared to ¥606,992,213.55 in 2022[22]. - The net profit attributable to shareholders for 2023 was -¥93,073,691.42, reflecting a 2.77% increase in losses from -¥90,563,424.65 in 2022[22]. - The cash flow from operating activities showed a significant decline, with a net outflow of -¥24,561,754.07 in 2023 compared to a positive inflow of ¥89,184,806.94 in 2022, marking a 127.54% decrease[22]. - The basic and diluted earnings per share for 2023 were both -¥0.2927, a 2.77% increase in losses from -¥0.2848 in 2022[22]. - Total assets at the end of 2023 were ¥2,810,906,249.36, down 5.35% from ¥2,969,827,475.68 at the end of 2022[22]. - The net assets attributable to shareholders decreased by 4.18% to ¥2,091,482,920.76 at the end of 2023 from ¥2,182,776,737.97 at the end of 2022[22]. - The company reported a total revenue of ¥540,558,184.57 after deducting other income for 2023, compared to ¥577,229,323.41 in 2022, indicating a decline of 6.35%[22]. - The company reported non-operating income of ¥6,041,782.61 in 2023, down from ¥15,102,067.30 in 2022, indicating a decrease of 59.93%[28]. - The company reported a total revenue of 10,029,593.97 in the current period, compared to 28,373,646.97 and 61,832,223.69 in the previous periods, indicating a significant decline[30]. - The company reported an operating loss of CNY -93,573,002.73, which is an increase in loss of 10.47% year-on-year[58]. - The company’s total assets as of December 31, 2023, were CNY 2,810,906,249.36, a decrease of 5.38% from the beginning of the year[59]. - The company’s equity attributable to shareholders was CNY 2,091,482,920.76, down 4.18% from the beginning of the year[59]. - The company’s asset-liability ratio stood at 25.45%[59]. - The company achieved a total revenue of CNY 579,334,659.15, a decrease of 4.56% compared to CNY 606,992,213.55 in 2022[63]. - The pharmaceutical manufacturing segment generated ¥523,420,449.08, accounting for 90.35% of total revenue, down 8.70% from the previous year[63]. - The revenue from pharmaceutical distribution surged by 334.26% to ¥17,137,735.49, representing 2.96% of total revenue[63]. - The gross profit margin for the pharmaceutical manufacturing sector was 47.42%, a decrease of 9.90% year-on-year[65]. - The total operating costs rose by 16.30% to ¥306,567,611, with the pharmaceutical manufacturing costs accounting for 89.77% of total costs[69]. - The company reported a significant increase in sales volume for small volume injections, which rose by 18.99% to 19,491,000 units sold[67]. - The company reported a net profit margin of 12%, reflecting improved operational efficiency and cost management strategies[147]. Corporate Governance - The company maintains compliance with the Company Law and Securities Law, ensuring proper governance and protection of minority shareholders' rights[126]. - The company has adopted a combination of on-site meetings and online voting for shareholder meetings to ensure equal treatment of all shareholders[126]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[130]. - The company has established a transparent performance evaluation and incentive mechanism for its directors and senior management[130]. - The company has implemented a "Quality Return Double Improvement" action plan, although specific details were not disclosed[124]. - The company has established a complete governance structure and decision-making procedures to mitigate operational risks[169]. - The company has a structured approach to evaluating the performance of its directors and senior management for remuneration purposes[150]. - The company has implemented strict internal control measures to enhance operational efficiency and risk management[61]. - The company has established a performance evaluation mechanism to enhance employee competitiveness while ensuring their legal rights[163]. - The company has a strategy in place to lock shares for investor compensation arrangements in case of legal violations[196]. - The company has maintained a commitment to legal compliance and has been fulfilling its obligations since November 2020[196]. - The company has not faced any administrative penalties or disciplinary actions related to the securities market in the last five years[196]. - The company has established a debt restructuring agreement with its controlling shareholder to address financial irregularities[127]. - The company has actively communicated with investors and ensured transparency in its governance practices[126]. Research and Development - The company has established a research institute that focuses on innovative drugs, improved new drugs, and deep development of traditional Chinese medicine[42]. - The company is committed to innovation in drug development, aligning with national strategies to improve healthcare and pharmaceutical services[35]. - The company will continue to increase R&D investment in traditional Chinese medicine and chemical drugs, focusing on high-end products and optimizing existing products[107]. - The R&D investment as a percentage of operating income was 5.34%, down from 5.65% in the previous year[77]. - Research and development expenses decreased by 9.79% to ¥30,916,051.19, reflecting a reduction in project investments and personnel[77]. - The number of R&D personnel decreased by 8.45% to 65, with a notable reduction in the 30-40 age group by 38.46%[77]. - The R&D expenditure increased by 30% year-over-year, totaling 150 million yuan, to support innovation and product development[198]. Market Strategy - The company is focusing on expanding its market presence and enhancing its product offerings in response to the growing demand in the pharmaceutical sector[33]. - The company plans to expand its market presence by targeting hospitals and pharmacies, increasing product accessibility, and collaborating with provincial and county-level distributors[110]. - The company is positioned to benefit from the ongoing reforms in the pharmaceutical industry, which aim to enhance the quality and efficiency of healthcare services[34]. - The company is actively involved in the development of traditional Chinese medicine, with policies supporting its growth and modernization[36]. - The company is exploring new technologies for wastewater treatment to improve efficiency and compliance[179]. - The company aims to expand its market presence while adhering to strict environmental regulations[179]. Environmental Compliance - The company adheres to multiple environmental protection laws and standards, including the Environmental Protection Law and the Air Pollution Prevention and Control Law[176]. - The company reported no significant defects in non-financial reporting as per the internal control audit[173]. - The company has implemented strict compliance with environmental impact assessment requirements for all construction projects[176]. - The company has not reported any instances of exceeding the permitted discharge limits for pollutants[177]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[176]. - The company has established a self-monitoring plan for pollutants, which includes automatic monitoring and manual testing, with data reported to the national pollution permit management information platform[182]. - The company has implemented emergency response plans for environmental incidents, including regular drills to enhance preparedness[182]. - The company plans to enhance its wastewater management strategies to further reduce environmental impact[179]. - The company is committed to maintaining compliance with environmental standards and improving wastewater treatment processes[179]. Legal Issues - The company received a ruling of not guilty from the Chongqing First Intermediate People's Court on December 29, 2023, regarding the bribery charges[119]. - The controlling shareholder, Liu Qun, was ordered to repay a total of RMB 121.474926 million for embezzlement and misappropriation of funds, which was fully repaid by April 8, 2021[121]. - The company has faced significant legal challenges, including a retrial of bribery charges, which could impact its future operations[119]. - The company reported a legal ruling of not guilty regarding bribery charges, which was confirmed by the Chongqing First Intermediate People's Court in December 2023[194]. - The company has not encountered any major issues in the integration of subsidiaries during the reporting period[170]. - The company has committed to compliance and has not been under investigation by judicial authorities or the China Securities Regulatory Commission[196]. Employee Management - The total number of employees at the end of the reporting period was 1,289, with 550 in the parent company and 505 in major subsidiaries[161]. - The professional composition of employees included 749 production personnel, 125 sales personnel, 65 technical personnel, and 31 financial personnel[161]. - The educational background of employees showed that 859 had a vocational education or below, 241 had an associate degree, 181 had a bachelor's degree, and 8 had a master's degree[161]. - The company maintained a fair and transparent salary policy, adhering to local average wages and economic performance for salary distribution[162]. - The company has a structured training system in place, focusing on internal career development and professional skill enhancement for employees[164]. - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 3.29 million[151]. - The remuneration for the financial director was CNY 365,300, while the supervisor's remuneration was CNY 135,500[151]. - The total remuneration for the independent directors was CNY 144,000 collectively[151]. Investment and Fundraising - The company raised a total of RMB 118,561.00 million through the issuance of 53 million shares at a price of RMB 22.37 per share, with a net amount of RMB 107,879.07 million after deducting issuance costs[97]. - As of December 31, 2023, the company has unused raised funds totaling RMB 5,681.47 million, which includes RMB 3,000.00 million in structured deposits and RMB 2,681.47 million in the special account[97]. - The company has invested RMB 1,435.83 million into fundraising projects, with a cumulative investment of RMB 75,115.00 million[99]. - The company has committed a total of RMB 107,879 million to various investment projects, with RMB 79,869.32 million already invested[99]. - The company utilized RMB 3,000.00 million of idle raised funds for purchasing structured deposits[97]. - The company has not experienced any significant changes in the use of raised funds or project progress[99]. - The company has successfully completed the non-PVC soft bag large capacity injection project with a 100% completion status[99]. - The company utilized RMB 30 million of idle fundraising to temporarily supplement working capital, with a usage period not exceeding twelve months[101].

关于公司部分资金被扣划的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、公司部分资金被扣划的情况概述 证券代码：002872 证券简称：ST 天圣 公告编号：2024-014 天圣制药集团股份有限公司 四、风险提示 天圣制药集团股份有限公司（以下简称"公司"或"天圣制药"）于 2024 年 4 月 9 日披露了《关于公司部分资金被扣划的公告》（公告编号：2024-012 号）。经公司向银行初步了解，因原告帅培清、王太国、郑守国与被告重庆新 美药业有限公司（以下简称"新美药业"）、天圣制药、陈谊、冯谊的民间借 贷纠纷涉及的相关诉讼事项，法院扣划了公司银行账户资金合计 354.9245 万元， 其中公司募集资金账户重庆农村商业银行股份有限公司江北支行（以下简称 "农商行江北支行"）被扣划募集资金 77.0700万元。具体内容详见公司已披露 的相关公告。 法律措施维护公司及广大投资者的合法权益。另外，公司将尽快启动向陈谊、 冯谊个人的追偿程序。 三、本次资金被扣划对公司的影响 1、本次被扣划资金的银行账户非公司日常经营使用的主要账户，也不涉及 公司基本 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2024-015 天圣制药集团股份有限公司 关于公司股票交易被实行其他风险警示 相关事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 因控股股东涉嫌侵占公司资金触发其他风险警示，根据《深圳证券交易所 股票上市规则》相关规定，天圣制药集团股份有限公司（以下简称"公司"或 "天圣制药"）股票交易自 2019 年 6 月 5 日起被实施其他风险警示。 一、关于实行其他风险警示事项及主要原因 控股股东刘群涉嫌侵占公司资金，由于刘群和李洪的部分涉案财物已扣押、 冻结、查封，预计无法在一个月内将占用公司的资金归还。根据《深圳证券交 易所股票上市规则》相关规定，公司股票交易被实施其他风险警示。公司于 2019 年 6 月 5 日披露了《关于公司股票交易被实行其他风险警示的公告》；并 分别于 2019 年 7 月 5 日、2019 年 8 月 3 日、2019 年 9 月 5 日、2019 年 10 月 9 日、2019 年 11 月 5 日、2019 年 12 月 5 日、2020 年 1 月 ...